Paul Peter Tak named to PharmaVoice’s 100 List
Pharma Voice’s 100 list is a prestigious compilation that recognizes influential leaders and innovators in the pharmaceutical and life sciences industry. Among the distinguished individuals acknowle…
The Story of Flagship Pioneering and The Future of Medicines
James is delighted to be joined by the accomplished Dr. Paul-Peter Tak, currently serving as the Venture Partner at Flagship Pioneering and holding the esteemed position of CEO at Kintai Therapeutic…
Careers in Discovery
Embark on an enriching exploration into the dynamic realms of Pharma and Biotech with “Careers in Discovery” – a captivating series that serves as your exclusive window into the captivating world of…
Podomatic: Paul-Peter Tak
In biotech, DR. PAUL-PETER TAK, the CEO of Kintai Therapeutics gives us a bigger picture of our gut – it’s not just your microbiome that plays a significant role in the recovery from illness.
Lis…
Bios Appoints Biotech Leader Paul Peter Tak, MD PHD as a Strategic Advisor
Cambridge, UK and Montreal, Canada – 5 May, 2021 – BIOS Health, a pioneer in the development of neural interfaces, has appointed world-renowned immunologist and biotechnology business leader, Paul P…
GSK Funds a New Startup with Immunometabolic Focus
Backed by GlaxoSmithKline and Boston’s SV Health Investors, a new biopharmaceutical company known as Sitryx launched with $30 million in a Series A funding round to develop disea…
EXCLUSIVE: Flagship Pioneering Company Kintai Therapeutics Focuses on Enteric Therapeutics
The vast majority of immune cells are found in the gut but historically, the gut has been viewed as a liability to drug development. The question of whether or not greater understanding of harnessin…
Industry veterans Paul Peter Tak and Eric Meldrum join Citryll’s Board
Citryll announced its Board has been strengthened with two industry veterans with impressive track-records.
Who is Paul-Peter Tak?
Paul Peter Tak, MD, PhD served as Professor of Medicine and C…
Candel Aims High In Next Stage Of Cancer Immunotherapy Mission
Emerging Company Profile: Candel Therapeutics, formerly known as Advantagene, has hired a new leadership team and is aiming for a Phase III data read-out in prostate cancer in 2023.
View Article:…
GlaxoSmithKline Scientist Steps Down to Join Flagship Pioneering
Dr Tak’s new role will help oversee scientific ventures to find transformative treatments for conditions such as cancer, neurodegenerative disease and autoimmune diseases.
https://www.businessle…
